NASDAQ$MRVI
Maravai LifeSciences Holdings Inc. · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Reported solid results driven by Nucleic Acid Production and Biologics Safety Testing revenues, while also updating revenue, Adjusted EBITDA, and Adjusted EPS guidance for 2022.
Maravai LifeSciences reported a revenue of $191.3 million for Q3 2022, with a net income of $99.7 million and Adjusted EBITDA margins of 69%. The revenue includes $16.4 million from Biologics Safety Testing, $48.4 million from Nucleic Acid Production base business, and $126.5 million from COVID-19 related CleanCap® revenue.
- Total revenues reached $191.3 million.
- Net income was $99.7 million.
- Adjusted EBITDA margins were 69%.
- Expanded mRNA raw material offering with GMP-grade N1-Methyl-Pseudouridine-5’-Triphosphate.
Headline financials
Revenue & EPS history
Maravai · Revenue · Quarterly
$189M
Revenue by segment
Maravai · $191M total across 2 segments · Q3 2022
- TriLink$175M-4.4%91.4%
- Cygnus$16.4M-1.5%8.6%
Forward guidance
Total revenue for 2022 is projected to be in the range of $880.0 million to $890.0 million, reflecting overall year-over-year growth of 10% to 11%. Adjusted EBITDA (non-GAAP) is now expected to be in the range of $650.0 million to $660.0 million. Adjusted fully diluted EPS (non-GAAP) is now expected to be in the range of $1.76 - $1.80 per share.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2022
-0.2%
Avg return
Earnings day
+2.1%
Avg return
5 days after
+1.1%
Avg return
30 days after
42%
10 / 24 earnings
Positive
+58.9%
Q4 2023
Best reaction
-36.7%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +23.4% | +10.9% | +27.5% | |
| Q4 2025 | +9.9% | +13.2% | -12.3% | |
| Q3 2025 | -0.7% | +12.5% | +28.0% | |
| Q1 2025 | -2.4% | -0.9% | +6.6% | |
| Q4 2024 | -6.4% | -13.2% | -31.4% | |
| Q3 2024 | -36.7% | -29.0% | -37.1% | |
| Q2 2024 | -6.7% | -4.3% | -0.4% | |
| Q1 2024 | +10.0% | +17.5% | -3.9% | |
| Q4 2023 | +58.9% | +57.0% | +66.5% | |
| Q3 2023 | -31.3% | -25.0% | -24.3% | |
| Q2 2023 | -3.5% | -10.1% | -5.7% | |
| Q1 2023 | -16.4% | +2.5% | -3.3% | |
| Q4 2022 | +6.9% | +3.2% | -2.4% | |
| Q3 2022 | -11.7% | -13.8% | -15.3% | |
| Q2 2022 | +2.2% | -3.5% | -20.7% | |
| Q1 2022 | +6.1% | -2.9% | +6.7% | |
| Q4 2019 | +1.4% | +1.1% | -9.7% | |
| Q4 2021 | -1.6% | +14.8% | +7.0% | |
| Q3 2020 | -1.7% | -0.4% | +6.3% | |
| Q3 2021 | +1.6% | +3.1% | +10.1% | |
| Q2 2021 | -5.7% | +8.8% | +0.6% | |
| Q1 2020 | +4.0% | +8.6% | +26.5% | |
| Q1 2021 | -4.8% | +2.1% | +13.1% | |
| Q4 2020 | -0.4% | -2.4% | -6.3% | |
| Q2 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro